Wedbush Maintains Outperform Rating for Adicet Bio: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Wedbush has maintained its Outperform rating for Adicet Bio (NASDAQ:ACET) but lowered its price target from $17.00 to $5.00. Adicet Bio's shares are currently trading at $1.33, and a move to $5.00 would represent a 275.94% increase.
November 09, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush has maintained its Outperform rating for Adicet Bio but lowered its price target. This could potentially lead to increased investor interest.
The maintained Outperform rating indicates that Wedbush still sees potential in Adicet Bio, which could attract investors. However, the lowered price target suggests a revision in expectations. The current share price is significantly lower than the target, indicating potential for growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100